Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2003-10-10

Original market date: See footnote 1

1973-12-31

Product name:

DEPO-MEDROL WITH LIDOCAINE

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

00260428

Product Monograph/Veterinary Labelling:

Date: 2018-05-03 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

PFIZER CANADA ULC
17300 Trans-Canada Highway
Kirkland
Quebec
Canada  H9J 2M5

Class: 

Human

Dosage form(s):

Suspension

Route(s) of administration:

Intra-Articular,  Intrabursal

Number of active ingredient(s):

2

Schedule(s):

Prescription  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

68:04.00   ADRENALS

Anatomical Therapeutic Chemical (ATC): See footnote 4

H02BX01  METHYLPREDNISOLONE, COMBINATIONS

Active ingredient group (AIG) number:See footnote 5

0201293001

List of active ingredient(s)
Active ingredient(s) Strength
LIDOCAINE HYDROCHLORIDE 10 MG / ML
METHYLPREDNISOLONE ACETATE 40 MG / ML

Application information

Related information

Contact us

Version 3.8.0
Date modified: